Compare Enveric Biosciences Inc (ENVB) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs DENTSPLY SIRONA Inc — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while DENTSPLY SIRONA Inc trades at $13.36 (market cap $2.68B). The key difference: DENTSPLY SIRONA Inc is far larger — about 503.8× Enveric Biosciences Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | XRAY | |
|---|---|---|
Market Cap | $5.32M | $2.68B |
Sector | Health | Health |
52-Week High | $17.40 | $16.85 |
52-Week Low | $1.28 | $9.64 |
Enterprise Value | $408.82K | $4.83B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
XRAY trades at $13.76, up 8.35% in 24 hours, with technical indicators showing a bullish trend. The stock has missed earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.36. Revenue declined to $3.68 billion in 2025, and the company reported a net loss of $598 million. Recent news highlights include distribution expansions and new AI-enabled product launches, while analyst sentiment remains mixed with a consensus price target of $13.33.
The outlook for XRAY is cautious due to persistent earnings misses and negative profitability, though technical momentum and strategic initiatives offer some upside potential. Key risks include margin pressure, high debt levels, and soft European demand. Investors should weigh the bullish technical signals against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
